Substances · Benzodiazepines and thienodiazepines
Desalkylgidazepam
- Preferred name
- Desalkylgidazepam
- IUPAC name
- 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
- Parent CAS number (reference)
- 28981-97-7
- Molecular formula
- C17H13ClN4
- Molecular weight
- 308.8 g/mol
- InChIKey
- VREFGVBLTWBCJP-UHFFFAOYSA-N
- PubChem
- CID 2118
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
Bromonordiazepam Gidazepam M1
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
Desalkylgidazepam
Receptor Telemetry & Mechanism of Action
Active N-desalkyl metabolite of gidazepam (bromonordiazepam) acting as a partial/selective GABA-A modulator with lower hypnotic sedation than triazolobenzodiazepines.
Biotransformation & Active Metabolites
Slow hepatic elimination with an extended ~80-hour plasma half-life.
Temporal Pharmacokinetics
Daytime-Leaning Anxiolytic Metabolite (Desalkylgidazepam) — Mild per-milligram potency (1 tablet = 1 mg; common literature range 3–6 mg) with gentle anxiolysis and long elimination half-life (~80 h).
- Onset 30–75 min
- Peak Window 2–4 h
- Total Window 8–14 h
- Residual / Half-Life 24–60 h residual (T1/2 ~80 h)
Mild per-milligram potency (1 tablet = 1 mg; common literature range 3–6 mg) with gentle anxiolysis and long elimination half-life (~80 h).
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
1–2 mg
Subtle threshold receptor activity (Daytime-Leaning Anxiolytic Metabolite (Desalkylgidazepam)).
Minimal baseline autonomic shift.
2–3 mg
Mild, clear-headed expression of primary class profile.
Light somatic modulation.
3–6 mg
Full characteristic neurochemical and perceptual profile documented in literature.
Moderate somatic relaxation, ataxia, or autonomic tone depending on class.
6–9 mg
Pronounced intensity, cognitive/motor impairment, or deep immersion.
Marked somatic load and heightened adverse-event sensitivity.
12+ mg
Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.
High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.
Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.
Elevated Hazard — Avoid
Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.
Caution / Receptor Attenuation
CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.
Structural Isomer & Sibling Comparison
Mild per-milligram potency (1 tablet = 1 mg; common literature range 3–6 mg) with gentle anxiolysis and long elimination half-life (~80 h).
Physicochemical Stability & Storage
Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.
Store sealed in a cool, dry, light-protected container away from humidity.
Cross-Tolerance & Dependence Profile
Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.
Chemical Architecture & Structural Profile
Desalkylgidazepam (8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C17H13ClN4 and a molar mass of 308.8 g/mol. The parent molecule is indexed under CAS registry number 28981-97-7 and in the NCBI PubChem database as CID 2118 (Standard InChIKey: VREFGVBLTWBCJP-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Desalkylgidazepam is indexed within the Benzodiazepines and thienodiazepines structural group. Triazolo/thienodiazepine reference compound; carries a high risk of synergistic respiratory depression if combined with opioids, alcohol, or other CNS depressants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- legislation.gov.uk — Misuse of Drugs Act 1971 & Psychoactive Substances Act 2016 — The National Archives (UK) (2026-11-12)